- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.


Nu.Q® Discover: Building a better NET model for drug development
- Share
- Tweet
- Share on Facebook
- Share


Dysregulation of the immune system in response to infection is a major health crisis, contributing to life-threatening conditions like sepsis, which causes millions of deaths annually. Our document highlights the critical role of neutrophils and neutrophil extracellular traps (NETs) in this process. While NETs are essential for fighting pathogens, their overproduction can lead to severe tissue damage and organ failure.
Developing effective treatments for sepsis and other immune dysregulation requires the ability to screen inhibitors of NET formation in a clinically relevant system. This document offers crucial insights into this area. Download it now to learn more about the latest research and potential therapeutic strategies.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields